IMM Investment

IMM Investment Corp. stands apart from the typical venture capital firm. Established in 1999 and headquartered in Seoul, the firm has grown into one of Asia's most formidable alternative investment platforms, managing over $7.5 billion in assets across venture capital, growth equity, private equity, and infrastructure. With 26 VC funds and 30 private equity fund-of-funds under management, IMM Investment has the scale and staying power to write meaningful checks across every stage of a company's lifecycle.

Under CEO Sung-bae Ji, IMM Investment has built a reputation for patient, partnership-driven investing. Unlike venture capital firms that rotate capital quickly, IMM takes a longer view—one that aligns with founders building transformative companies over 5-10 year horizons. This approach has produced a portfolio that spans robotics, biotech, enterprise software, and digital media, with several companies reaching unicorn status or successful exits.

What makes IMM Investment particularly distinctive is its position within the Korean ecosystem. As a domestic firm with deep relationships across Korean conglomerates, universities, and government agencies, IMM can offer portfolio companies introductions and partnerships that foreign VCs simply cannot replicate. For founders building bridges between Korea and global markets, this network is often the decisive factor.

The firm operates as a multi-asset platform, which means it can follow capital needs from earliest seed rounds through growth equity and even into infrastructure plays. This flexibility means IMM often leads rounds at stages where other domestic VCs would typically follow. For founders who want a lead investor that can grow alongside them, IMM Investment is worth serious consideration.

While IMM Investment has historically been associated with Korean startups, the firm has shown increasing interest in companies that leverage Korean technology excellence for global markets. Robotics, AI, semiconductor equipment, and advanced manufacturing are particular areas where Korean companies have structural advantages—and where IMM Investment has accumulated deep sector expertise.

IMM Investment's thesis centers on backing Korean technology founders building companies with global competitive moats. The firm looks for ventures that leverage Korea's structural advantages—advanced manufacturing capabilities, world-class semiconductor infrastructure, deep engineering talent pools—to build differentiated products. The focus is not simply on Korean market capture, but on building companies that can compete internationally.

Within Information Technology, IMM targets enterprise software, AI and machine learning applications, cybersecurity, and digital infrastructure. Within Healthcare and Biotech, the firm invests in novel therapeutics, medical devices, and digital health platforms—particularly those with platform potential or strong IP positions. The Manufacturing focus has evolved toward automation, robotics, and smart factory solutions, reflecting Korea's strength in these domains.

The firm's investment approach is fundamentally sector-agnostic in terms of business model—it will back B2B software, hardware, services, and deep tech equally—so long as there is a clear technological differentiation and a path to significant scale. IMM prefers to invest when there is early evidence of product-market fit, even if revenue is not yet substantial. Traction metrics, customer concentration, and burn efficiency all receive scrutiny.

IMM Investment takes a collaborative approach to ownership. Rather than taking board control and driving operational changes, the firm prefers to support founders with strategic resources—customer introductions, partnership deals, follow-on capital coordination—and let the management team drive execution. This partner-first posture is one reason founders often cite IMM as their preferred lead investor for subsequent rounds.

The firm has demonstrated willingness to invest across multiple stages, from seed rounds of a few million dollars to Series B and growth rounds exceeding $50 million. For the largest opportunities, IMM has shown ability to lead deals that set Korea's venture record. In 2026, IMM led Holiday Robotics' ₩150 billion (approximately $107 million) financing round—a testament to the firm's capacity to back winners at scale.

IMM Investment has maintained an aggressive deployment pace through 2024 and 2025, with activity accelerating into 2026. The firm's recent portfolio additions reflect its conviction in AI-enabled robotics, next-generation biotech, and digital commerce infrastructure. Notably, IMM participated in Orum Therapeutics' $100 million Series B in late 2025, a round that also included KB Investment, Weiss Asset Management, and GS Ventures to advance the company's protein degrader pipeline targeting Alzheimer's and immune disorders.

In early 2026, IMM Investment made a notable entry into Japanese digital media by participating in Brave Group's Series E round, which raised ¥8 billion (approximately $53 million) and was led by Gree Holdings. The investment reflects IMM's strategy of supporting founders who are building cross-border platforms that bridge Northeast Asian markets—a distinctive thesis that very few VCs operate with.

Mediwhale, a South Korea-based healthcare company, received investment from IMM in March 2026, continuing the firm's active engagement in the healthtech sector. The firm also backed Illimis Therapeutics' $42 million Series B in mid-2025, a round that included LB Investment and GS Ventures, targeting novel therapeutics for neurodegenerative disease.

The ₩150 billion financing for Holiday Robotics in April 2026 represented the largest domestic VC round of the year and signaled IMM's willingness to concentrate capital in companies where it sees transformative potential. Holiday Robotics' development of humanoid robots for industrial automation has positioned it at the center of one of Korea's most promising technology export categories.

Beyond new investments, IMM has demonstrated commitment to its existing portfolio through follow-on rounds. The firm's LP base—dominated by Korean institutional investors including pension funds, insurers, and corporate treasuries—provides the stable capital base needed to support companies across multiple financing rounds without pressure to exit prematurely.

Market conditions in 2025 and early 2026 have influenced IMM's approach, with the firm becoming more selective at seed stage while remaining opportunistic at growth stage. The robotics and biotech sectors have remained priority areas where valuations have been more resilient, while some consumer-facing software categories have seen more pronounced correction.

IMM Investment's portfolio reflects over 25 years of conviction investing in Korea's technology ecosystem. The firm has invested in 47 companies as of April 2026, with 7 new investments made in the preceding 12 months. The portfolio spans multiple sectors and stages, with several companies achieving unicorn valuations or successful exits through IPO and M&A.

Holiday Robotics stands as one of IMM's highest-profile current holdings. The company is developing humanoid robots for industrial automation, an area where Korea's manufacturing expertise provides structural advantages. IMM led the company's ₩150 billion financing in April 2026, reflecting confidence in the team's ability to commercialize advanced robotics for global markets. The round valued Holiday Robotics at a level approaching unicorn status.

Musinsa, Korea's leading fashion e-commerce platform, has raised over $330 million with backing from IMM Investment alongside marquee global investors including KKR, Sequoia Capital, and SoftBank. The company has become the dominant player in Korean fashion e-commerce and has begun expanding into Japan and Southeast Asia—a trajectory that aligns with IMM's thesis on Korean consumer platform companies scaling regionally.

Orum Therapeutics represents IMM's conviction in advanced biotech. The company is developing targeted protein degradation therapeutics, a cutting-edge approach to treating cancer and neurodegenerative diseases. IMM participated in the company's $100 million Series B in late 2025, a round that included several prominent Korean and international investors. The therapeutic modality has attracted significant pharma interest, and an exit via acquisition or partnership could be on the horizon.

Illimis Therapeutics, another biotech holding, raised a $42 million Series B in mid-2025 with IMM's participation. The company's focus on novel small molecule therapeutics for Alzheimer's and immune disorders addresses massive unmet medical need. IMM's willingness to back early clinical-stage companies reflects the firm's long investment horizon and tolerance for technical risk.

Brave Group, a Japanese digital media and content company, received IMM's investment in early 2026 as part of an ¥8 billion Series E round led by Gree Holdings. The investment reflects IMM's cross-border thesis and the firm's belief that Japanese digital content platforms have significant room for consolidation and growth—a view that has proven prescient as the Japanese digital media market has matured.

IMM Investment evaluates potential investments based on sector thesis fit, founder background, and market opportunity sizing. The firm has a pronounced preference for technical founders with deep domain expertise—this is particularly evident in the biotech and robotics portfolios, where multiple portfolio company CEOs hold advanced degrees or have prior entrepreneurial exits. The team looks for founders who have thought through the full stack of their business, from technology development to customer acquisition.

Market opportunity assessment at IMM focuses on addressable market size and the pathway to becoming a dominant player within it. The firm is skeptical of markets that require complex multi-sided coordination before reaching escape velocity, preferring businesses that can achieve strong SaaS unit economics early and scale efficiently. Market sizing is expected to support a $100 million+ revenue opportunity at maturity.

Competitive moat analysis is rigorous. IMM expects founders to articulate clearly why their technology, distribution, or brand creates durable differentiation. In biotech, this means strong IP positions and clear regulatory pathways. In enterprise software, it means demonstrated switching costs and expansion revenue dynamics. In robotics, it means manufacturing partnerships and hardware integration capabilities that competitors cannot easily replicate.

Financial metrics matter, but IMM's team understands that early-stage companies often have limited history. The firm looks for evidence of customer traction—revenue growth, net revenue retention, gross margin progression—and expects founders to present realistic models grounded in actual customer behavior rather than top-down projections. Burn rate and runway are scrutinized for understanding of how capital will be deployed and when the next financing milestone will be required.

Founder quality and composition receive intensive evaluation. IMM prefers founding teams with complementary skill sets—technical depth paired with commercial acumen—and looks for evidence that the team has worked together before or has a track record of execution in the relevant domain. The firm's partners often describe looking for 'founder-market fit,' where the specific background and capabilities of the team are uniquely suited to the opportunity at hand.

Scalability of business model is a key determinant in IMM's investment decisions. The firm is drawn to businesses where marginal cost of serving additional customers is low, where the product can be standardized and delivered at scale, and where the company can achieve operating leverage as it grows. This preference manifests in a portfolio that skews toward software and platform businesses alongside selective hardware plays.

Connecting with IMM Investment is most effective through warm introductions from within the Korean startup ecosystem. The firm has deep roots in the university system—particularly KAIST, Seoul National University, and Korea University—where many promising founders emerge. Introductions from portfolio company CEOs, domestic institutional investors, or Korean conglomerate innovation teams carry significant weight and typically result in an initial meeting within weeks.

For founders without immediate ecosystem connections, building a relationship with IMM's investment team through conference participation and Korean startup events is a viable path. The firm sponsors and attends major Korean venture conferences, and the investment team is accessible to founders who demonstrate traction and domain expertise. Demonstrating knowledge of IMM's existing portfolio and articulating why your company is complementary rather than competitive is a strong signal.

Cold outreach through the firm's website is accepted but less effective. If submitting cold, IMM's team expects a clear articulation of why your company aligns with their sector thesis, what differentiates your approach, and what milestones you are targeting. The pitch should demonstrate awareness of IMM's portfolio and explain specifically why your company is a fit. Generic mass outreach is filtered quickly.

When preparing for an initial meeting with IMM, expect to discuss your technology differentiation, target market sizing, business model, customer traction, and financing history in depth. The investment team will probe your assumptions and challenge your projections—be prepared to defend every claim with data or credible reasoning. Anticipate questions about your competitive positioning and your path to becoming the market leader.

Following up after initial meetings is expected. IMM's investment process typically spans 4-8 weeks from initial meeting to term sheet, though this varies with deal complexity and internal bandwidth. Send progress updates on material milestones—new customer signings, product launches, financing news—but avoid overwhelming the team with excessive outreach. The goal is to remain visible without creating friction.

Even if your current round does not result in an investment, maintaining the relationship can be valuable. IMM sees many companies at early stages and may revisit in subsequent rounds as the business evolves. Additionally, the firm can make introductions to other investors, potential customers, or strategic partners even without an investment—making the relationship potentially valuable before a financing event concludes.

For IMM Investment, financial preparedness is a meaningful signal of founder quality. The firm wants to see that founders understand the mechanics of their business—the SaaS unit economics, the path to breakeven, the cash conversion cycle, and the implications of different growth scenarios on capital needs. Founders who present clear, grounded financial models and can explain their assumptions demonstrate the analytical rigor that IMM values.

Korean institutional investors—IMM's LPs—place significant emphasis on financial rigor when evaluating fund performance, and IMM's team reflects that orientation in its portfolio company expectations. Understanding your KPIs deeply, tracking the metrics that drive your business, and being able to explain variance from plan are table stakes for a productive relationship with IMM.

Working with a fractional CFO can meaningfully improve your positioning in IMM's evaluation process. Professional financial leadership helps founders build investor-ready financials, construct realistic scenario models, and confidently navigate the due diligence process. For early-stage companies without dedicated finance leadership, this external support is often the difference between a smooth process and one that surfaces avoidable concerns.

Our team has worked with numerous companies raising capital from Korean institutional investors, including firms with IMM Investment's involvement. We understand what the investment committee looks for in financial presentations and can help you prepare materials that present your business with clarity and credibility. From financial model construction to investor pitch preparation, we ensure you are positioned for success.

Financial projections should reflect genuine scenario analysis. IMM's team will probe the assumptions underlying your forecasts and challenge optimistic scenarios that lack evidentiary support. Building a model that presents base, upside, and downside cases with clear triggering events and milestones demonstrates intellectual honesty and strengthens your credibility with sophisticated investors.

Key performance indicators should be tracked relentlessly and reported consistently. IMM will want to understand not only where your metrics stand but how they trend over time and how they compare to relevant benchmarks. Being able to speak fluently about your metrics—retention rates, cohort behavior, conversion funnels, payback periods—signals operational mastery and builds investor confidence in your ability to execute.

Whether you are preparing to pitch IMM Investment or any of Korea's other leading institutional investors, professional financial preparation can set you apart. Our experience with venture fundraising in the Korean market gives us insight into how sophisticated investors evaluate opportunities and what they look for in founder presentations.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and tips for securing funding. Whether you are looking for seed-stage investors or growth equity firms, you will find valuable insights in our VC firm guides.

Finding the right investor for your startup is crucial to your success. Take the time to research potential investors and understand their investment thesis before reaching out.

Our guides cover major venture capital firms as well as emerging managers that may be a better fit for your company's specific needs and stage.